Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by retiredcopon Jun 02, 2021 11:05pm
162 Views
Post# 33316833

RE:RE:RE:RE:RE:RE:FDA decision will have waterfall effect on other companies

RE:RE:RE:RE:RE:RE:FDA decision will have waterfall effect on other companiesThis is my view of this whole situation...Regardless of whether Biogen gets approval.or not...pmn is going to be focusing on the comments that the fda makes....we know regardless of the decision... the fda will be expressing concerns that pmn is going to target when they roll.out the things that they feel.pmn310 can do. .what better way to gain approval with the regulators and their peers then to address what shortcomings aducunamab had....this is a perfect storm that is developing for.us to tackle..hence that constant reminder of beat in class ..because we correct what others before us could.not....many of.the old crew of shareholders I.have talked to in the past month say the same thing " they have never been more confident or as optimistic in the future of the company as they are right now...just all around positive vibes out there right now"
<< Previous
Bullboard Posts
Next >>